THE Australian Competition and Consumer Commission has granted interim authorisation permitting Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA) to discuss and implement strategies to support the continued supply of medicines, during the COVID-19 crisis.
MA CEO, Elizabeth de Somer, welcomed the announcement.
"[The] authorisation underscores the importance of an integrated supply chain for our medicines," she said.
"And I thank the GBMA for working alongside us in addressing the challenges we now faces as a result of COVID-19."
The authorisation came into effect on Fri, and follows a similar move for wholesalers.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Apr 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Apr 20
